Application and Use of Transformative Emerging Technologies in Cancer Research

To view funding opportunities for the Application of Emerging Technologies for Cancer Research program, click here.

To view abstracts for Application of Emerging Technologies for Cancer Research awards, click here.

To view abstracts for the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Program awards, click here.

Objectives and Scope

These RFAs are intended to support projects to evaluate the usefulness of emerging technologies in appropriate biological contexts in order to assess reproducibility and produce preliminary data toward a biological or clinical question. Technologies proposed for these RFAs should be sufficiently advanced in development to be applied in a relevant clinical or biological context.

Researchers may propose, in the R21 phase, to continue minor refinement of newly developed technologies or minor adaptations of existing technologies to new uses. The R33 phase should be used for applying the technology in a relevant setting to generate the preliminary biological data to prove that the technology functions reproducibly and effectively in the chosen biological context. These projects should provide investigators with sufficient data to demonstrate the capabilities of the technology in a biologically relevant setting. These data may then be used by the investigator or by others to propose new projects using the technology to answer biological or clinical questions, through other existing program announcements (for example, see the Division of Cancer Prevention and the Specialized Programs of Research Excellence) or as investigator-initiated R01 applications. The data generated may also be used by technology developers in partnership with clinical or biological investigators with questions that the new technology could elucidate or to partner with industry to further refine the technology into a commercial product.

It is expected that investigators who developed successful cancer-relevant technologies under previous IMAT initiatives will propose projects for these RFAs. However, these RFAs are not limited to technologies developed under the IMAT Program. Investigators may propose to begin to utilize any emerging cancer-relevant technology. Areas of emerging technologies of interest to be applied in these projects include, but are not limited to, those technologies that enable:

In vitro scanning for and identification of the sites of chromosomal aberrations which reflect inherited aberrations or somatic alterations resulting from aging or oxidation, or exposure to radiation or carcinogens, including those that are suitable for scaling for use across whole genomes, detecting DNA adducts, or detecting rare variants in mixed populations
In vitro scanning for and identification of sites of mutations and polymorphisms that reflect inherited aberrations or variations, or somatic alterations resulting from aging, oxidation, or exposure to radiation or carcinogens, including those that are suitable for scaling for screening whole genomes, detecting DNA adducts, or identifying infrequently represented mutations in mixed populations of DNA molecules
Technologies for detection and characterization of nucleic acid sequences of novel exogenous infectious agents that may be present in human cancer
Highly specific and sensitive detection of specific mutations
Detecting mismatch and recombinational DNA repair related to cancer susceptibility and drug sensitivity
In vitro multiplexed analysis of the expression of genes
In vitro detection of expression of proteins and their modified forms, including technologies suitable for expansion to profiling of all proteins expressed in cells, detecting rare variants in mixed populations, and detecting protein adducts involved in chemical mutation
Monitoring the function of proteins and genetic pathways, including measurement of ligand-protein complexes and technologies for monitoring protein function of all members of a class of proteins or a complete genetic pathway
Delineating molecular expression, function and analysis at the cellular level in the context of both the whole body and in situ , including molecular imaging technologies suitable at this scale, contrast agents, gene amplification techniques and related data analysis tools
Technologies to elucidate molecular modifications of macromolecules that may be indicative of and critical to the transformation process
Delivery technologies and approaches to enable faster and more accurate delivery of molecular and cellular labels and drugs to and within cells for research and treatment with the overall goals being speed, accuracy, and biocompatibility
Development of high-throughput, quantitative assays for epigenetic alterations, e.g., acetylation and methylation, in promoter region of genes and histone proteins isolated from biological fluids and tissues

For all projects proposed, it will be important to substantiate the ultimate value of and role for the technology in deciphering the molecular anatomy of cancer cells or analyzing the molecular profile of the individual. Inherent in this early technology application is the potential for ultimately transferring knowledge gained, technology, and/or methodology to other laboratories or the clinic. In the case of technologies intended for use on clinical specimens or in patients, applications from or collaborations with investigators involved in the clinical research of cancer are encouraged.